[1] |
Juraschka K, Taylor MD. Medulloblastoma in the age of molecular subgroups: a review[J]. J Neurosurg Pediatr, 2019, 24(4): 353-363.
doi: 10.3171/2019.5.PEDS18381
|
[2] |
Louis DN, Perry A, Reifenberger G, et al. The 2016 world health organization classification of tumors of the central nervers system: a summary[J]. Acta Neuropathol, 2016, 131(6): 803-820.
doi: 10.1007/s00401-016-1545-1
|
[3] |
Zou H, Poore B, Broniscer A, et al. Molecular heterogeneity and cellular diversity: implications for precision treatment in medulloblastoma[J]. Cancers (Basel), 2020, 12(3): 643.
doi: 10.3390/cancers12030643
|
[4] |
Tamayo-Orrego L, Charron F. Recent advances in SHH medulloblastoma progression: tumor suppressor mechanisms and the tumor microenvironment[J]. F1000Res, 2019, 8: F1000 Faculty Rev-1823.
|
[5] |
PDQ Pediatric Treatment Editorial Board. Childhood medulloblastoma and other central nervous system embryonal tumors treatment (PDQ): health professional version. bethesda (MD): National Cancer Institute (US); 2002.
|
[6] |
Thompson EM, Hielscher T, Bouffet E, et al. Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis[J]. Lancet Oncol, 2016, 17(4): 484-495.
doi: S1470-2045(15)00581-1
pmid: 26976201
|
[7] |
Laurent JP, Chang CH, Cohen ME. A classification system for primitive neuroectodermal tumors (medulloblastoma) of the posterior fossa[J]. Cancer, 1985, 56(7 Suppl):1807-1809.
pmid: 4027916
|
[8] |
Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma comprises four distinct molecular variants[J]. J Clin Oncol, 2011, 29(11): 1408-1414.
doi: 10.1200/JCO.2009.27.4324
pmid: 20823417
|
[9] |
Ramaswamy V, Remke M, Bouffet E, et al. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus[J]. Acta Neuropathol, 2016, 131(6): 821-831.
doi: 10.1007/s00401-016-1569-6
pmid: 27040285
|
[10] |
杜淑旭, 李苗, 张金, 等. 儿童髓母细胞瘤的预后因素和生存分析[J]. 中华实用儿科临床杂志, 2019, 34 (24): 1886-1890.
|
[11] |
Khatua S, Song A, Sridhar DC, et al. Childhood medulloblastoma: current therapies, emerging molecular landscape and newer therapeutic insights[J]. Curr Neuropharmacol, 2018, 16(7): 1045-1058.
doi: 10.2174/1570159X15666171129111324
pmid: 29189165
|
[12] |
Rolland A, Aquilina K. Surgery for recurrent-medul loblastoma: a review[J]. Neurochirurgie, 2021, 67(1): 69-75.
doi: 10.1016/j.neuchi.2019.06.008
pmid: 31351079
|
[13] |
Packer RJ, Zhou T, Holmes E, et al. Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children's Oncology Group trial A9961[J]. Neuro Oncol, 2013, 15(1): 97-103.
doi: 10.1093/neuonc/nos267
|
[14] |
Huang PI, Lin SC, Lee YY, et al. Large cell/anaplastic medulloblastoma is associated with poor prognosis—a retrospective analysis at a single institute[J]. Childs Nerv Syst, 2017, 33(8): 1285-1294.
doi: 10.1007/s00381-017-3435-9
|
[15] |
Cavalli FMG, Remke M, Rampasek L, et al. Intertumoral heterogeneity within medulloblastoma subgroups[J]. Cancer Cell, 2017, 31(6): 737-754.
doi: S1535-6108(17)30201-5
pmid: 28609654
|
[16] |
Rutkowski S, von Hoff K, Emser A, et al. Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis[J]. J Clin Oncol, 2010, 28(33): 4961-4968.
doi: 10.1200/JCO.2010.30.2299
pmid: 20940197
|
[17] |
Gajjar A, Robinson GW, Smith KS, et al. Outcomes by clinical and molecular features in children with medulloblastoma treated with risk-adapted therapy: results of an international phase III trial (SJMB03)[J]. J Clin Oncol, 2021, 39(7): 822-835.
doi: 10.1200/JCO.20.01372
pmid: 33405951
|
[18] |
Menyhárt O, Győrffy B. Molecular stratifications, biomarker candidates and new therapeutic options in current medulloblastoma treatment approaches[J]. Cancer Metastasis Rev, 2020, 39(11): 211-233.
doi: 10.1007/s10555-020-09854-1
|
[19] |
Perreault S, Ramaswamy V, Achrol AS, et al. MRI surrogates for molecular subgroups of medulloblastoma[J]. AJNR Am J Neuroradiol, 2014, 35(7): 1263-1269.
doi: 10.3174/ajnr.A3990
|
[20] |
Taylor MD, Northcott PA, Korshunov A, et al. Molecular subgroups of medulloblastoma: the current consensus[J]. Acta Neuropathol, 2012, 123(4): 465-472.
doi: 10.1007/s00401-011-0922-z
pmid: 22134537
|
[21] |
Rutkowski S, Bode U, Deinlein F, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone[J]. N Engl J Med, 2005, 352(10): 978-986.
doi: 10.1056/NEJMoa042176
|
[22] |
Geyer JR, Sposto R, Jennings M, et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group[J]. J Clin Oncol, 2005, 23(30): 7621-7631.
pmid: 16234523
|
[23] |
Guerrini-Rousseau L, Dufour C, Varlet P, et al. Germline SUFU mutation carriers and medulloblastoma: clinical characteristics, cancer risk, and prognosis[J]. Neuro Oncol, 2018, 20(8): 1122-1132.
doi: 10.1093/neuonc/nox228
|
[24] |
Menyhárt O, Győrffy B. Molecular stratifications, biomarker candidates and new therapeutic options in current medulloblastoma treatment approaches[J]. Cancer Metastasis Rev, 2020, 39(1): 211-233.
doi: 10.1007/s10555-020-09854-1
|